Ketogenic diet in epilepsy: an updated review by Dudzińska, Magdalena
27
R
e
v
ie
w
 p
a
p
e
r
Ketogenic diet in epilepsy: an updated review
Magdalena Dudzińska
Paediatric Neurology Department
Chorzów General Hospital, Poland
Correspondence
Dr n. med. Magdalena Dudzińska
Paediatric Neurology Department
Chorzów General Hospital
41-500 Chorzów, ul. Truchana 7, Poland
phone (48) 32 3490027; cell (48) 601 53 12 87
e-mail: mdudzinskapl@gmail.com
SUMMARY
Introduction. Finding an effective epilepsy treatment has been a challenge in medicine for centuries. It 
is especially difficult to treat drug-resistant epilepsy, which accounts for 20–30% of epilepsy cases, even 
after the introduction of numerous new anti-epileptic drugs (AEDs). This gives an incentive to search for 
therapies other than pharmacotherapy, e.g. the ketogenic diet (KD).
Aim. The present review paper aims to present the current state of knowledge regarding the effectiveness 
of the KD, its mechanism of action, indications, method of treatment and potential adverse effects.
Material and method. The review covers relevant most recent (up to March 2018) papers using PubMed 
and Medline databases.
Results and discussion. The history of the KD dates back to ancient times. It was believed to be very prom-
ising at the beginning of the last century, but then was temporarily ‘forgotten’ and has been undergoing a 
second renaissance since around 1990. It is currently recognised in most countries. The KD is administered 
mainly to children but over the last few years there have been attempts to use it in adults as well. The 
theoretical basis of the diet consists in the fact that it ‘mimics’ the metabolic state of an organism subject 
to fasting by replacing the basic source of energy for the brain, that is glucose, with ketone bodies, which 
are a product of fat breakdown. In spite of scientific progress, the exact mechanism underlying the KD is 
still not known. Its effectiveness, at first mainly as an add-on therapy, and in some cases as the first-line 
monotherapy, is rated quite highly (> 50% seizure reduction in > 50% patients; of which in 20–30% of pa-
tients seizures are reduced by > 90%). It can be used to treat all types of epileptic seizures after excluding 
contraindications. The KD, like any medical therapy for serious illnesses, may cause adverse effects. Most 
of them are mild, can be prevented, and if they occur, can be fairly easily treated
Conclusion. The KD as add-on therapy or as monotherapy is a medical treatment of epilepsy adminis-
tered under medical supervision.
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INTRODUCTION
Epilepsy is one of the most common disorders of the 
nervous system. It is a health problem as well as a so-
cial and economic one. Approximately 50 million peo-
ple around the world suffer from epilepsy, with around 
3.4 million of them in Europe. Every year 2 million new 
cases are diagnosed. The incidence in children is rough-
ly of 5–7 per 100 000 per year, whereas the prevalence 
is of 20–60 per 100 000 (Rezaei et al., 2017; Kinderen 
et al., 2011). In spite of significant progress in pharma-
cotherapy, the percentage of non-responding patients 
has remained unchanged. The new generation AEDs, 
undoubtedly better tolerated and generally safer, have 
not, unfortunately, proved significantly more effective 
against epileptic seizures than the classical medicines 
(Hartman, Vining, 2007). Normally, the first admin-
istered AEDs leads to freedom from seizures in 50% of 
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patients, the second in around 11%, the third in around 
3%, whereas all subsequent AEDs work in only 0.8% of 
patients (Mohanraj, Brodie, 2006). Still only around 
60% of patients are completely free from seizures or 
achieve substantial control, whereas 30% are refracto-
ry to this form of therapy. Patients who suffer from sei-
zures in spite of the administration of two subsequent, 
appropriately-selected AEDs that are well applied and 
tolerated, are diagnosed with refractory epilepsy (Kwan 
et al., 2010). Seizures persisting despite treatment may 
cause developmental delay in children, cognitive im-
pairment, poor life quality of the patient and their fam-
ily or even sudden death. A diagnosis of refractory ep-
ilepsy forces the physician to resort to therapies other 
than pharmacological: resective surgery, vagus nerve 
stimulator (VNS), depth electrode stimulation or the 
ketogenic diet (KD). In patients whose seizures are re-
lated to a localised epileptic focus, neurosurgery is con-
sidered the first-line treatment. In patients who do not 
qualify for neurosurgery, VNS implant or the KD are 
considered. Compared to VNS, the KD is easier to use 
and its potential anticonvulsant effect is observed ear-
lier – usually after just 2–4 weeks (in the case of VNS it 
takes several months) (Kossoff et al., 2009b).
The KD is recognised all over the world; it is used 
in more than 60 countries. It is characterised by high 
fat content, protein content appropriate for age and 
low carbohydrate content. In the KD, a so-called ‘ke-
togenic ratio’ is determined (4 :1, 3 :1, 2 :1), i.e. a weight 
ratio of grams of fat to grams of protein and carbohy-
drates combined (respectively 4, 3 or 2 g of fat for 1 g 
of proteins and carbohydrates combined) (Kossoff et 
al., 2009a). Over the last few years, interest in this ther-
apy has been increasing both in epilepsy centres and 
among parents of underage patients as well as in adult 
patients. The number of publications on the KD has 
been growing rapidly. In the years 1991–1999, from 
5 to 34 papers per year were added to the PubMed da-
tabase; in the years 2000–2010 it was between 34 and 
125; in 2011–2017 the number of publications per year 
exceeded 150. In 2017 as many as 282 publications on 
the KD appeared in PubMed. More in-depth knowl-
edge of the mechanism of action, indications and less 
restrictive versions of the KD is acquired. In 2012 in the 
United Kingdom, NICE (National Institute of Health 
and Clinical Excellence) advised in its recommenda-
tions that KD be considered for use in children who 
had failed to respond to appropriate pharmacothera-
py administered so far (Nunes et al., 2012).
AIM
The present review aims to present the current state of 
knowledge regarding the effectiveness of the KD, its 
mechanism of action, indications, method of treatment 
and potential adverse effects.
MATERIAL AND METHOD
The review includes 175 relevant and most recent (up 
to March 2018) publications identified using PubMed 
and Medline databases.
RESULTS AND DISCUSSION
History of ketogenic diets
The history of the KD is very long, dating back to an-
tiquity and biblical times. Fasting was observed to 
have a beneficial effect on reducing devastating sei-
zures which was reported in the works of Hippocrates 
(5th century B.C.) and in the Gospel according to Mark. 
Interest in the dietary treatment of epilepsy was revived 
at the beginning of the 20th century, a time when phe-
nobarbital (PB) and bromides were the only availa-
ble AEDs. French physicians Guelpa and Marie (1911) 
were the first to describe the impact of fasting on re-
ducing seizure intensity. In the United States, an osteo-
pathic physician Conclin and Macfadden (1922) wrote 
the first reports regarding the beneficial effect of fast-
ing on epileptic seizures. In 1921, during an American 
Medical Association (AMA) convention, Rawle Geyelin 
presented observations of a group of 30 patients aged 
3.5–35 years, that fasted for 20 days and which led to 
absolute seizure freedom in 87% of patients. Woodyatt 
(1921), having used the diet in diabetic patients, drew 
attention to the presence of acetone and beta-hydroxy-
butyric acid (BHBA) in the blood of both healthy peo-
ple subject to fasting and those on a low carbohydrate 
and high fat diet. At the same time Wilder (1921) and 
then Peterman (1925) from the Mayo Clinic presented 
a proposal of a diet in which most of the energy came 
from fat and the metabolic processes arising while on 
the diet mimicked the metabolic state achieved during 
fasting. Due to the fact that the diet induced the state 
of ketosis, which likely plays a role in fighting epileptic 
seizures, this diet was named the KD. General rules for 
its application have not changed till this day (Wheless, 
2008). By 1930, the KD had been used in 272 children 
in the USA (A.D.B., 1931) as monotherapy or, in some 
patients, with added phenobarbital. In 1938, the intro-
duction of phenytoin (PHT), expected to be more effec-
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tive and easier to use than the diet, perceived as a diffi-
cult therapy, hampered its wider spreading. More AEDs 
were successively introduced (since the 1950s – 26 in 
total) (Elia et al., 2017) and they have raised hopes for 
complete seizure control; however, around 30% of pa-
tients still do not reap the expected benefits of phar-
macotherapy. In the 1980s the diet was taken up once 
more by professor Freeman and his co-workers from 
Johns Hopkins Hospital in Baltimore, USA, in a lim-
ited number of patients (around 10 a year). As a result, 
in 1992 they published a report summing up KD’s ef-
fectiveness (mostly as add-on therapy) in 58 children 
with epilepsy (Kinsman et al., 1992). Since the results 
of the first multi-centre studies – evaluating the effi-
cacy of the KD – were presented at the American Epi-
lepsy Society (1996), interest in this therapeutic meth-
od has been growing (number of reports from ca. 100/
year in the nineties to over 200 in 2017). The principles 
for using the KD in children were published in 2009 
(Kossoff et al., 2009a). As more insight is gained into its 
mechanism of action, the KD is increasingly being used 
in diseases other than epilepsy (Stafstrom, Rho, 2012).
Mechanism of action of the ketogenic diets
Though there is no doubt as to the efficacy of the KD 
in refractory epilepsy treatment, its precise mecha-
nism of action remains unknown. In the case of phar-
macotherapy, in contrast, the mechanisms of many 
AEDs are known (e.g. through voltage-dependent so-
dium channels), which might suggest their potential 
efficacy in epilepsy treatment; nevertheless, it has not 
brought about a decrease in the percentage of patients 
with refractory epilepsy, the underlying mechanism of 
which cannot be entirely explained either (Rho, Staf-
strom, 2012). Given the fact that the KD is effective in 
many types of epilepsy, it must be acknowledged that 
its mechanism of action is undoubtedly very complex. 
During fasting, or when the carbohydrate supply is 
lowered and the fat supply simultaneously increased, 
large amounts of free fatty acids (FFA), unable to pass 
the blood-brain barrier, appear in blood. In liver mito-
chondria, in the beta-oxidation process, they are con-
verted via acetyl-CoA into ketone bodies: acetone, ace-
toacetate, and β-hydroxybutyric acid. They are subse-
quently released into the circulatory system, from where 
they easily cross the blood-brain barrier. During the 
application of the KD, the metabolic status accompa-
nying fasting is ‘mimicked’ which means that the cells 
of many organs, especially of the central nervous sys-
tem, use fat breakdown products, i.e. ketone bodies, as 
their main source of energy replacing glucose. The ke-
tone bodies, instead of glucose, become the source of 
acetyl-CoA for the Krebs cycle. This is a key process for 
the KD’s action. Moreover, the ketones constitute an 
essential building block in the process of biosynthesis 
of cell membranes in the developing brain. As the ef-
ficacy of the KD in epileptic seizure reduction is prov-
en, it is clear that the KD impacts on neuronal excit-
ability (Bough, Rho, 2007). Multiple reports indicate 
that its mechanism of action is particular and differ-
ent from epilepsy therapies used so far (Rogawski et al., 
2016). Among recognised mechanisms of the KD’s ac-
tion, emphasis is put on the role of caloric restriction, 
decreased glucose supply and glycolysis reduction, as 
well as on the direct impact of ketone bodies and free 
fatty acids (including PUFAs – polyunsaturated fatty 
acids) on triggering a series of complex biochemical, 
hormonal and even genetic processes (Masino, Rho, 
2012; Danial et al., 2013; Rogawski et al., 2016). Ketone 
bodies, free fatty acids and limited glucose supply influ-
ence both directly and indirectly epileptic seizure con-
trol through diverse mechanisms. Available studies in-
dicate that in order to achieve a full anticonvulsant ef-
fect, co-occurrence of all three factors above is neces-
sary (Bough, Rho, 2007). For the KD’s action, it is es-
sential to decrease the glucose supply, reduce glycolysis 
and elevate the blood level of ketone bodies, which rep-
resent an alternative ‘fuel’ for cells. In the process of an-
aplerosis (replenishing missing intermediates participa-
ting in the Krebs cycle – TCA) they supply the Krebs cy-
cle, responsible for generating energy (ATP) and indi-
rectly responsible for neurotransmitter production (Ro-
gawski et al., 2016). That reduced glucose and elevated 
fatty acids cause chronic ketosis – which triggers a se-
ries of complex biochemical, hormonal or even genet-
ic processes – has been confirmed. Activation of these 
processes affects the stabilisation and/or stimulation 
of cellular metabolism. As a result, it inhibits neuronal 
dysfunctions accompanying convulsant activity. The 
scope of the present paper does not allow for a detailed 
presentation of the numerous interdependent elements 
(established so far or currently being investigated) that 
determine the final, indisputably-confirmed effect of 
the KD on epileptic seizure reduction. The most im-
portant ones are, however, worth mentioning. The im-
pact of the KD on mitochondrial function is obvious. It 
consists in increased biogenesis of these cell organelles, 
elevated production of energy carrier molecules (ATP) 
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inside them, leading eventually to the build-up of en-
ergy reserves in cells. In this process, an essential role 
is played by PUFAs boosting UCPs (uncoupling pro-
teins) that stimulate mitochondria to produce more en-
ergy (Bough et al., 2006). Energy production in cells is 
conditioned by NAD (nicotinamide adenine dinucle-
otide). The latest reports point to a probable increase 
in the NAD+/ NADH ratio as a key factor in the KD’s 
action (Elamin et al., 2017). Moreover, the KD helps to 
reduce oxidation stress in neurons. Enhanced expres-
sion of UCPs induces decreased mitochondrial mem-
brane potential, and consequently reduced ROS (reac-
tive oxygen species) production. A rise in energy pro-
duction in mitochondria and a drop in the number of 
free radicals contribute to the prevention of neuronal 
dysfunction, convulsions or even neurodegeneration 
(Bough et al., 2006; Greco et al., 2016). Furthermore, 
reduced glucose and the state of ketosis cause the acti-
vation of ATP-sensitive potassium channels (KATP) in 
neurons which results in reducing their convulsant ex-
citability (Bough, Rho, 2007; Masino, Rho, 2012). The 
KD also causes changes in metabolism and in the re-
lease of neurotransmitters. The synthesis of the inhib-
iting neurotransmitter GABA is increased, while its 
breakdown slows down, thus increasing its levels in the 
cerebrospinal fluid. Besides this, ketosis (BHBA and 
acetoacetate) directly triggers a decrease in presynap-
tic release of the excitatory neurotransmitter – gluta-
mate which directly leads to the inhibition of excitato-
ry glutamate-dependent synaptic transmission (Bough, 
Rho, 2007; Masino, Rho, 2012; Danial et al., 2013; Ko-
ssoff, Wang, 2013). Increased concentration of norep-
inephrine and adenosine, related to restricted glucose 
supply, is also crucial for the anticonvulsant effect of 
the KD. Through activation of adenosine A1 recep-
tors, adenosine impacts the ATP-dependent potassium 
channels mentioned above (Masino, Rho, 2012). Among 
many aspects unpinning the KD’s action, one that has 
been recently stressed is the increase in the leptin lev-
el. Leptin is an endogenous peptide causing a decrease 
in synaptic excitability (Rho, Stafstrom, 2012). Atten-
tion should be paid to the specific role of PUFAs in the 
twofold reduction in neuronal excitability, directly and 
indirectly achieved through the activation of fatty acid 
receptors, PPARs (peroxisome proliferator-activated re-
ceptors) in particular (Bough, Rho, 2007; Masino, Rho, 
2012; Kossoff, Wang, 2013).
Many authors emphasise the KD’s influence on in-
hibiting the mTOR (mammalian target of rapamycin) 
pathway in the brain (its hyperactivity has a convul-
sant effect and conduces to epileptogenesis), this is yet 
another way in which the KD produces an anticonvul-
sant and antiepileptic effect (McDaniel et al., 2011; Da-
nial et al., 2013; Kossof, Wang, 2013). Ketones (KBs) and 
their metabolic intermediates (acetyl-CoA, aspartate, 
PUFAs), among other effects, have a strong influence 
on the expression of genes linked to cellular metabo-
lism and ROS resistance (Youngson et al., 2017). The 
period of around 2 weeks that is needed to reveal the 
anticonvulsant effect of the KD correlates with the time 
required for alterations to gene expression, mitochon-
drial proliferation and uncoupled proteins’ upregula-
tion (Maalouf et al., 2009). During treatment with the 
KD, the glucose level in the blood remains correct, de-
spite its minimum intake when on the diet, owing to the 
fact that it is produced via gluconeogenesis from ami-
no acids and glycerol released from triglycerides in the 
beta oxidation process. Thanks to that cells that abso-
lutely require glucose, such as red blood cells, devoid of 
mitochondria, can satisfy their metabolic needs (Wal-
czyk, Wick, 2017). The KD probably also affects the gut 
microbiome’s composition by increasing the quantity 
of bacteria producing short-chain fatty acids (SCFAs), 
which then pass from the bloodstream into the brain, 
where they are one of the factors impacting the regu-
lation of seizure activity (Newell et al., 2016). Until re-
cently it was believed that, due to the limited ability of 
ketones to cross the blood-brain barrier in adults, the 
KD could not be used in this age group. This assump-
tion has turned out to be incorrect. It has been prov-
en that in disease-related stress, the number of pro-
teins transporting ketones (MCT – monocarboxic acid 
transporters) to the brain increases (Azevedo de Lima 
et al., 2014). This is evidenced by the growing number 
of reports on the KD’s effectiveness in the treatment 
of adult epilepsy.
In summary, the processes described above, as well 
as some others not mentioned in the present paper, pro-
duce the following results: an increase in neuronal en-
ergy reserves (increased mitochondrial biogenesis, in-
creased production of ATP), improved mitochondrial 
function, a reduction in oxidative stress leading to neu-
ronal damage provoked by ROS and reactive nitrogen 
species (RNS), the modification of neuronal circuits 
and cell properties towards reinforcement and nor-
malisation of neuronal function, stabilisation of cell 
membranes, alteration to the excitability and plasticity 
of neurons, and the attenuation of inflammatory reac-
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tions in nervous tissue. Although the exact mechanism 
of action of the KD has not been entirely understood, it 
has been assumed on the basis of previous studies that 
ketones alter the metabolism of neurons, affect the lev-
el of neurotransmitters and regulate the development 
of neurons (Zhang et al., 2018). KD therapy combines 
numerous beneficial mechanisms of action, contribut-
ing to success in the treatment of epilepsy not only by 
inhibiting epileptic seizures but also by affecting the 
course of epilepsy (Boison, 2017). Ultimately, this com-
plex mechanism leads not only to the already known 
anticonvulsant action of the KD but also produces its 
neuroprotective, anti-inflammatory and epileptogen-
esis-inhibiting effects (hence the long-lasting anticon-
vulsant effect persisting after discontinuation of the 
treatment) (Maalouf et al., 2009; Danial et al., 2013; 
Masino, Rho, 2012; French et al., 2017, Chorągiewicz 
et al., 2010). The clinical effect of the KD cannot be ex-
plained with reference to only one mechanism of action 
because, as in the case of AEDs, it is multifaceted and 
caused by many factors. Even though the AEDs lead to 
seizure control in many patients, unfortunately not all 
patients become seizure-free through pharmacothera-
py. The KD makes it possible to control seizures in pa-
tients with refractory epilepsy. The therapeutic effect 
of the KD results from its impact on the metabolism 
and is completely different from the mechanism of ac-
tion of the AEDs. Studies on the KD may bring about 
entirely new therapeutic strategies in refractory epi-
lepsy. Further research on the KD mechanism is nec-
essary (Rogawski et al., 2016).
The KD in epilepsy – evaluation of effectiveness
Many epileptologists consider the KD to be one of the 
most effective treatments for paediatric epilepsy as 
add-on therapy, but sometimes as monotherapy (even 
for first-line therapy in some situations), apart from re-
sective neurosurgery (in cases where neurosurgery is 
indicated) (Kossoff et al., 2009b).
Case studies
Hundreds of papers published over the last 30 years 
present similar results: in patients on the KD, follow-
ing treatment for 3–12 months, a >50% reduction in 
seizures (as compared to the period preceding the diet) 
is observed in >50% (24–83%) of patients treated with 
the KD, and in 30% (30–46%) of those patients seizures 
decrease by >90%, while 10–18 % become entirely sei-
zure-free (Vining et al., 1998; Henderson et al., 2006; 
Keene, 2006; Neal et al., 2008; Li et al., 2013b; Martin 
et al., 2016). In 1998, Freeman et al. published obser-
vations of 150 patients after 3, 6 and 12 months of KD 
treatment in whom they achieved the same results. In 
2001, the same authors published a paper assessing the 
results of treatment in this group of 150 patients 3 and 
6 years after its initiation. 13% of patients remained sei-
zure-free, whereas in 14% seizures had been reduced 
by 90–99%. In 29 patients it had been possible to dis-
continue the AEDs, while 28 patients were taking only 
1 AED. Fifteen patients continued the KD (Heming-
way et al., 2001).
Meta-analyses
Since 2000, several meta-analyses evaluating the ef-
fectiveness of the KD, based on retrospective and pro-
spective studies, have been published. All presented 
the same results. They indicated a seizure reduction 
of > 90% in about one third of patients; > 50% in 30–
50% of patients and complete freedom from seizures 
in 15–16 % of patients (Lefevre, Aronson, 2000; Levy, 
Cooper, 2003; Henderson et al., 2006; Keene, 2006). All 
of the above meta-analyses pointed to the lack of ran-
domised controlled trials (RCTs) trials among the pa-
pers assessed and highlighted the necessity of under-
taking RCTs in larger groups of patients. They con-
cluded that, in spite of the lack of such trials. the results 
obtained were sufficient to rate the KD as effective in 
treating seizures in children with intractable epilepsy.
Controlled studies
The first RCT was undertaken in London and published 
in 2008 (Neal et al., 2008). Children were randomly as-
signed to a group receiving the KD after 1 month of in-
itial observation (54 patients) and a control group (49 
patients) who started receiving the diet after 4 months. 
In the course of the 3-month observation period the 
first group experienced seizure reduction of > 50% in 
38% of patients, whereas in the control group only 6% 
of patients (p < 0.0001) experienced such a decrease. Re-
duction of seizures by > 90% was observed in 7% and 
0% of patients respectively (p = 0.0582).
The following year, the first and so far the only blind-
ed crossover study was published. It concerned children 
with Lennox-Gastaut syndrome. The patients were ran-
domised into two groups: the first group received flu-
ids sweetened with saccharin (experimental group), the 
second received fluids sweetened with glucose (placebo). 
The results, even if statistically insignificant (P = 0.07), 
Ketogenic diet in epilepsy: an updated review
32
indicated a more substantial seizure reduction in chil-
dren in the experimental group (receiving saccharine) 
(Freeman et al., 2009). Due to methodological diffi-
culties it is practically impossible to conduct a blinded 
crossover study on patients receiving the KD.
Recently numerous RCT evaluating the treatment of 
intractable epilepsy in children via the use of the KD 
were published. It is worth discussing some of them. 
Comparisons of the KD’s efficacy were conducted tak-
ing into account the following parameters: the efficacy 
of the KD initiated with or without fasting, without sig-
nificant differences found (Bergqvist et al., 2005), the 
effect of the KD at a 4 : 1 ratio and at a 3 : 1 ratio – with 
better seizure control at the 4 : 1 ratio (Seo et al., 2007), 
the modified Atkins diet (MAD) with the use of 10g 
of carbohydrates a day as compared to the group re-
ceiving 20g a day with better results in the first group 
(Kossoff et al., 2007), children treated with the classic 
KD at both the 2.5 : 1 and 4 : 1 ratio; less adverse effects 
were noticed at the lower ratio (Raju et al., 2011). El- 
Rashidy compared children receiving the classic KD at 
the 4 : 1 ratio and the MAD to children who continued 
to receive their pharmacological treatment applied so 
far, and the best anticonvulsant effect was achieved in 
the children on the 4 : 1 KD (second best in patients on 
MAD) (El-Rashidy et al., 2013). A significantly higher 
effectiveness of MAD as compared to traditional treat-
ment (care as usual – CAU) was noted by Sharma et al. 
(2013). In 2016, a meta-analysis taking into account the 
above-mentioned RCT studies was conducted. In con-
clusion, its authors declared the KD to be a promising 
and valuable method of treatment for refractory epilep-
sy. At the same time they stressed the necessity of fur-
ther research (Martin et al., 2016). No clear advantage of 
the KD over MAD was identified except in the younger 
children (< 2 years old) in whom the KD was more effi-
cient at seizure reduction (Kim et al., 2016). Then Lam-
brechts et al. (2017) compared 26 children who received 
the KD to 22 who remained on CAU. The effects were 
assessed after 4 months. In the group treated with the 
KD, a > 50% seizure reduction was observed in 50% of 
patients (including 3 patients who became seizure-free 
and 3 other patients whose seizures dropped by > 90%). 
In the control group, a > 50% seizure reduction was ob-
served in only 5 patients (18.2%), including 2 seizure-
free and 1 with a > 90% reduction (p = 0.022).
Distant effect of the KD
Patel et al. (2010) evaluated the distant effect of the KD 
treatment in 101 patients who had discontinued the diet 
on average 6 years before the study was conducted (0.8–
14 years). A > 50% seizure reduction was maintained in 
80% of patients. In accordance with the multiannual 
observations of numerous authors, the KD not only re-
duces epileptic seizures, but also has an impact on the 
improvement of functioning regardless of the degree 
of seizure control (in > 80% patients), better concen-
tration and ability to learn, improved behaviour, bet-
ter sleep structure (prolonged REM phase), the possi-
bility of AEDs reduction (in around 30% of patients) 
and, as a result, a visibly improved quality of life (QoL) 
(Pulsifer et al., 2001; Hallböök et al., 2007; Hallböök et 
al., 2012; Sharma, Jain, 2014; Zhu et al., 2016; IJff et al., 
2016; Bruce et al., 2017).
Reports of EEG studies
A beneficial effect of the KD on the EEGs has also been 
reported, especially on the decrease of interictal epilep-
tiform discharges, just after 1 month of treatment. Pa-
tients in whom such a result is visible are more likely 
to experience seizure reduction after 3 months. Even 
a short treatment with the KD may cause an increase 
in beta activity, which suggests that the KD has an ef-
fect similar to that of AEDs with a GABAergic mech-
anism of action (Kessler et al., 2011). Improved back-
ground activity is also observed (Li et al., 2013a).
When to use the KD – indications
Metabolic diseases with epilepsy
Two inborn errors of metabolism related to the conver-
sion of carbohydrates are an absolute indication for the 
ketogenic diet (treatment of choice): glucose transport-
er type 1 deficiency (GLUT1DS) and pyruvate dehydro-
genase complex deficiency (PDHD). Drug resistant ep-
ileptic seizures are one of their main symptoms. Due 
to the difficulty of using glucose as the brain’s source 
of energy in these disorders, ketone bodies constitute 
an alternative ‘fuel’ for the brain.
The KD in GLUT1 deficiency. GLUT-1DS is a dis-
ease related to impaired transport of glucose. Decreased 
delivery of glucose to the brain across the blood-brain 
barrier by the GLUT1 transporter results in a lack of 
energy for the brain. The clinical symptoms include 
refractory seizures, early-onset encephalopathy, mi-
crocephaly, motor disorders and developmental delays. 
Lowered concentration of glucose in the cerebrospinal 
fluid (below 40 mg/dL) points to a GLUT1DS diagno-
sis which can be confirmed by detection of the SLC2A1 
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gene mutation (in 80–90% of patients). The KD is the 
treatment of choice in this disorder: ketones replace 
glucose as an energy source, thus enabling the proper 
functioning of nerve cells which leads to a subsidence 
in epileptic seizures and suppression of the progress of 
any developmental delay (Klepper, Leiendecker, 2007). 
The KD should be introduced as soon as possible once 
the diagnosis has been made (Kossoff et al., 2009 a; Lee, 
2012; Elia et al., 2017).
The KD in pyruvate dehydrogenase complex defi-
ciency (PDHD). PDHD is a rare genetically determined 
neurometabolic disorder, caused by impaired glucose 
conversion. Deficiency of the pyruvate dehydrogenase 
enzyme prevents the conversion of pyruvate to acetyl 
coenzyme-A, consequently disrupting energy produc-
tion in the Krebs cycle. The KD is a treatment of choice. 
While on the diet there is a switch from glucose to ke-
tones as the basic source of energy for the brain, allow-
ing the body to ‘bypass’ the metabolic block and, con-
sequently, prevent progressive brain damage (Wexler et 
al., 1997; Barañano, Hartman, 2008; Prasad et al., 2011; 
Lee, 2012; Sofou et al.; 2017).
The KD in epilepsy
Doose syndrome. The KD treatment is undoubted-
ly beneficial in Doose syndrome – myoclonic astatic 
epilepsy (MAE), which accounts for 1–2% of epilep-
sies below 9 years of age. Seizure reduction > 50% has 
been observed in > 50% of patients, and its complete 
disappearance in 30% (Caraballo et al., 2006; Kilaru, 
Bergqvist, 2007; Bergqvist, 2012). Stenger et al. (2017) 
observed the resolution of seizures after 6 months in 
54% of children, while after 2 months of therapy the 
reduction in seizures exceeded 70% in 86% of patients. 
In addition, earlier introduction of KD treatment cor-
related with a greater improvement in cognitive func-
tion and a higher remission rate. Based on the NICE CG 
137 guidelines, the KD is recommended as the first-line 
treatment for MAE (Nunes et al., 2012; McTague, Cross, 
2013). The exceptional efficacy of the KD in MAE can 
be explained by the presence in some patients of mu-
tations in the SLC2A1 gene, associated with GLUT1 
DS – according to Mullen et al. (2011) in 5%. MAE may 
also be associated with a mutation in the SLC6A1 gene, 
responsible for GAT-1 dysfunction (GABA transport-
er protein), causing a reduction in the GABA level in 
the synaptic cleft, and consequently convulsions. The 
KD, affecting the increase in GABA concentration and 
its activity in neurons, applied in a patient with MAE, 
in whom this mutation was confirmed, led to freedom 
from seizures (Palmer et al., 2016).
Early onset absence seizures. Mutations in the 
SLC2A1 gene have been described by Arsov et al. 
(2012 a) and by Thouin and Crompton (2016) in 10–
12% of patients with early-onset absence seizures (be-
low 4 years of age). In recent years, more emphasis has 
been put on the fact that epilepsy with generalised sei-
zures may be the only manifestation of GLUT1 DS (Ar-
sov et al., 2012 b). Therefore, the particular efficacy of 
the KD in genetically determined epilepsies with gen-
eralised seizures can be explained by the presence of 
SLC2A1 mutation in some patients. Basically, in idio-
pathic epilepsies with generalised seizures, approxi-
mately 1% of patients present with the mutation in the 
SLC2A1 gene which sheds light on the efficacy of the 
KD treatment in these conditions.
Childhood and juvenile absence epilepsy. Groomes 
et al. (2011) reported a very good outcome in these pa-
tients on the KD. The likelihood of the occurrence of 
GLUT1 DS, as well as of other mutations responsible for 
the development of early epilepsy with absence seizures 
and other refractory idiopathic epilepsies with general-
ised seizures, should incline doctors to test patients for 
these conditions and to consider earlier and wider use 
of the KD in these types of epilepsy (Elia et al., 2017).
Dravet syndrome. Reports on the efficacy of the 
KD in Dravet syndrome – a severe myoclonic infan-
tile epilepsy – have been proliferating. Numerous au-
thors reports similar results: over 60% of patients with 
reduction of seizures by > 50% and about 10% seizure-
free (Caraballo et al., 2005; Caraballo, 2011; Kang et al., 
2005; Dressler et al., 2015 b). Nabbout et al. (2011) dem-
onstrated the benefits of KD equally in children with 
Dravet syndrome receiving stiripentol. As well as sei-
zure reduction, the KD had a positive effect on behav-
ioural disorders and hyperactivity.
West syndrome, or infantile spasms (IS). West syn-
drome is one of the types of epilepsy that might po-
tentially derive the greatest benefit from the KD treat-
ment (Kossoff et al., 2009 a). Numerous reports indi-
cate the KD’s efficacy in West syndrome refractory to 
pharmacotherapy. Nordli et al. (2001) was one of the 
first authors to present the effects of the KD on seizure 
reduction in children with IS. Many papers described 
using the KD in West syndrome in groups of patients 
comprising from 17 to 104 infants. A > 50% reduction 
in seizures was observed in 60–70% of children after 
3 months of treatment, in 64–72% after 6 months, and 
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in 77–100% after 1 year. 32–53% of infants achieved 
a seizure-free outcome after 1–6 months of KD treat-
ment (Kossoff et al., 2002; Eun et al., 2006; Pires et al., 
2013; Lee et al., 2013; Dressler et al., 2015 a). Enhanced 
development was seen in 62%, EEG improvement in 
35%, while in 29% a reduction in the doses of co-ad-
ministered AEDs was made possible (Hong et al., 2010). 
Additionally, carers noticed the children experienced 
improved quality of life (Kayyali et al., 2014). Prezioso 
et al. (2018) published a review of 13 papers from the 
years 2005–2016 comprising in total 341 children with 
IS. Despite the heterogeneity of methodologies and 
groups of patients described, the results were compa-
rable. On average in 35% freedom from seizures was 
achieved while in 60% the reduction was of >50%. The 
KD is considered to be a second-line treatment in re-
fractory West syndrome (Hong et al., 2010; McTague, 
Cross, 2013). Some reports on its efficacy and safety as 
a first-line treatment have also emerged (Kossoff et al., 
2008a; Hong et al., 2010; Kossoff, Wang, 2013). The KD 
treatment in West syndrome is usually continued for 
6–8 months, while in other epilepsies it is typically ap-
plied for 2 years. (Kossoff et al., 2009b; Kang et al., 2011). 
If seizures in West syndrome persist after using the KD 
for 1 month, additional treatment should be considered 
(van der Louw et al., 2016). In all the reported studies, 
a better effect was observed in children who were old-
er at the time of diagnosis, with a shorter seizure his-
tory and fewer AEDs previously used.
Lennox-Gastaut syndrome (LGS). LGS is one of 
the most severe childhood epilepsies. It can have dif-
ferent aetiologies: in 65–75% it is symptomatic (genet-
ic-structural-metabolic), in other cases the cause of the 
disease remains unknown. It accounts for 1–10% of all 
childhood epilepsies. LGS may be considered a ‘sec-
ondary network epilepsy’ where the seizure discharges 
spread in the intrinsic cognitive brain network, which 
explains progressive intellectual deterioration accom-
panying the seizures (Archer et al., 2014; Asadi-Pooya, 
2018). Treating this group of patients represents a par-
ticular challenge and its long-term outcome is often un-
satisfactory (Mastrangelo, 2017). In 2012, Lemmon et 
al. conducted a retrospective evaluation of the KD’s ef-
ficacy in 71 children with LGS. In 51% of children sei-
zures were reduced by > 50% after 6 months, in 23% by 
> 90%, and 1% remained seizure-free. The results after 
12 months were similar. Caraballo et al. (2014), Zhang 
et al. (2016) and Sharma et al. (2015) obtained even 
better results in children with LGS. In addition, the 
authors proved that the improvement in background 
EEG activity and the decrease in interictal epileptiform 
discharges after the introduction of the KD correlates 
with better seizure control and may be a prognostic 
factor for therapeutic efficacy in patients with LGS. In 
the treatment algorithm for LGS, elaborated by Cross 
et al. (2017), the KD found a place next to pharmaco-
therapy and neurosurgery. The authors suggest using 
this method in some patients relatively early, once the 
first-line medicines (valproic acid [VPA] + lamotrigi-
ne [LTG]) have failed, even before introducing rufina-
mide (RFN). The rapid response to treatment with the 
KD (within 3 months) in children in whom it is going 
to be effective is an indication that the KD should be 
tried early in LGS therapy.
Super refractory status epilepticus (SRSE). In recent 
years, there has been a ‘revolutionary’ change in the ap-
proach taken regarding the use of KD in urgent situa-
tions and especially in SRSE. We can classify a case as 
SRSE if it persists after 24 hours of intensive anaesthet-
ic treatment has been initiated or if it recurs after this 
time during attempts to discontinue treatment (Appa-
vu et al., 2016). Reports confirming the effectiveness 
of the KD in the treatment of SRSE have been appear-
ing in print since 2008. Kossoff and Nabbout (2013) 
analysed 10 publications (2008–2012), describing a to-
tal of 32 cases of children and adults, in whom SRSE 
had a different aetiology and different variants of the 
KD were used. In 41% of patients, SRSE was caused by 
autoimmune or inflammatory diseases accompanied 
by fever (encephalitis, Rasmussen syndrome). In this 
group fever induced refractory epileptic encephalopa-
thy (FIRES) in school age children was also diagnosed. 
The KD in SRSE was introduced after at least 24 hours 
of ineffective pharmacotherapy. A disappearance of the 
seizures was observed in 40–100% (78% on average) of 
treated patients and occurred within 1–19 days (average 
7.0) (Kossoff, Nabbout, 2013; Appavu et al., 2016; Fari-
as-Moeller et al., 2017). In emergency situations such 
as SE, or in patients already receiving the KD, if enter-
al feeding is impossible (e.g. due to ileus or other seri-
ous gastrointestinal disorders), it is possible to use the 
parenteral route (intravenous) as an emergency solu-
tion (Strzelczyk et al., 2013; Farias-Moeller et al., 2017; 
Dressler et al., 2018). An opinion on the effectiveness 
of the KD in new-onset refractory status epilepticus 
(NORSE) and in the course of FIRES was presented 
at the first international symposium on these diseases 
(Gaspard et al., 2018). Further research on the optimal 
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use of the KD in SE is needed (e.g. when and how should 
it be introduced? How long should it continue?). In the 
case of refractory status epilepticus, effective treatment 
with the KD can directly save lives (Kossoff, Nabbout, 
2013; Dulac, Takahashi, 2013). FIRES is a type of ep-
ilepsy that often poorly responds to treatment, with 
an epileptic status and fever at the onset, in previous-
ly healthy school-age children, in whom neuroinfec-
tion has been excluded, and is likely to cause progres-
sive developmental disorders. The KD may be the on-
ly effective therapeutic option in these cases (Nabbout 
et al., 2010, Kramer et al., 2011; van Baalen et al., 2017).
Tuberous sclerosis complex (TSC). The KD in TSC 
treatment deserves special consideration. It is an ac-
knowledged fact that hyperactivity of the mTOR path-
way plays an important role in the pathogenesis of TSC 
(and probably also in other epilepsy syndromes, by pro-
moting epileptogenesis). It is also recognised that one 
of the mechanisms at work in the KD consists in hin-
dering this process (Mc Daniel et al., 2011; Danial et 
al., 2013). The epilepsy in TSC is highlighted as a con-
dition in which the use of the KD is particularly bene-
ficial (Kossoff et al., 2005; Kossoff et al., 2009 a; Park et 
al., 2017). As a third-line treatment, it is recommend-
ed in IS in the course of TSC, especially in children 
who cannot undergo neurosurgical treatment (Cura-
tolo et al., 2012).
Epilepsies with other etiologies. Epilepsy with a dif-
ferent etiology may also respond unexpectedly well to 
the KD treatment. The positive result of KD treatment 
in epilepsy caused by hypoxic-ischemic encephalopa-
thy was observed by Thammongkol et al. (2012): a re-
duction in seizures exceeding 50% after 3 months in 
4 out of 8 children, maintained in 3 out of the 4 that 
remained on the diet after 12 months. Epilepsy result-
ing from the malformation of cortical development, 
including focal cortical dysplasia (FCD), accounts for 
approximately 50% of all refractory epilepsies in chil-
dren and adults and, especially in children, constitutes 
the main indication for neurosurgical treatment. De-
spite its symptomatic character, it may respond partic-
ularly well to treatment with the KD (Jung et al. 2008; 
Thammongkol et al., 2012; Wang, Zhou, 2016). The KD 
in children with FCD probably alters disease progres-
sion by weakening the remodelling of chromatin, the 
main regulator of gene expression and functional cel-
lular adaptation (Stafstrom, Rho, 2012). It is interesting 
to note that the best result (64.7% with > 50% seizure 
reduction) was demonstrated in children whose mal-
formations were due to abnormal post-migrational de-
velopment compared to abnormal neuronal prolifera-
tion or abnormal neural migration (Pascal et al., 2018).
The results obtained by many authors (although only 
in small groups of patients so far) also indicate the effec-
tiveness of the KD in symptomatic epilepsy caused by 
structural changes in the brain and suggest it is worth 
considering implementing the KD even in epilepsy that 
could potentially benefit from surgical treatment. The 
question of whether to apply it in all patients and at 
what stage of treatment (before or after neurosurgery) 
remains unanswered (Jung et al., 2008; Cross, 2013).
The use of the KD in infants. The use of the KD in 
infants merits particular consideration. Currently, it is 
believed that the KD is effective and safe also in this 
particular group of patients, and its use should be con-
sidered at the early stages of treatment rather than as 
a treatment of ‘last resort’. The effectiveness of treat-
ment with the KD in this age group is comparable or 
even greater than in older children (Nordli et al., 2001; 
Klepper et al., 2002; Dressler et al., 2015 a). Safe KD 
therapy in infants is possible based on ready ketogen-
ic formulas, supplemented with necessary vitamins 
and microelements. In some cases, partial breastfeed-
ing is also possible (Thiele, 2013; Dressler et al., 2015 a, 
Wilmshurst et al., 2015a; Wilmshurst et al., 2015b; van 
der Louw et al., 2016, Ashrafi et al., 2017; Sampaio et 
al., 2017). In 2016, a group of paediatric neurologists 
and dietitians published guidelines on the use of the 
KD in infants, presenting detailed rules on the safe 
use of the KD in this special group of patients (van der 
Louw et al., 2016).
The use of the KD in adults. In spite of the increas-
ing use of the KD in children, until recently there had 
been no interest in this treatment as a therapeutic op-
tion for refractory epilepsy in adults. However, wider 
use of more liberal versions of the KD – a diet based on 
middle-chain triglycerides (MCT), MAD and low glyca-
emic index diet (LGIT) – makes it easier to accept this 
method of epilepsy treatment in adults. Besides this, 
in recent years the number of children on the KD has 
been growing which means that ‘adult’ neurologists 
will need to take over their treatment at some point 
(Kossoff, Dorward, 2008; Cervenka et al., 2016 a; Nab-
bout et al., 2017).
A > 50% seizure reduction was reported in > 40% of 
adult patients treated with the KD or the MAD, includ-
ing the cases when the diet was used as monotherapy 
in newly diagnosed epilepsy (Klein et al., 2010; Cer-
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venka, Kossoff, 2013; Cervenka et al., 2016 a; Cerven-
ka et al., 2016 b).
A very interesting, recently published report pre-
sents the use of the KD as a non-pharmacological al-
ternative to AEDs in two pregnant women – in one as 
a monotherapy and in the other combined with LTG. 
The diet was well-tolerated and healthy children were 
born at term (van der Louw et al., 2017). In general, the 
biggest problem in adult patients related to compliance 
with the strict rules of the therapy (Klein et al., 2010; 
Cervenka et al., 2016a; Cervenka et al., 2016 b; Schoeler, 
Cross, 2016; van der Louw et al., 2017). The increasing 
demand for KD treatment of epilepsy in adult patients 
justifies conducting randomised trials on its efficacy 
and cost effectiveness in this group of patients (Mar-
tin-McGill et al., 2017).
The KD can be used in all age groups and indepen-
dently of coexisting developmental disorders.
In Poland, the KD has been included in the recom-
mendations of the Polish Society of Paediatric Neurol-
ogists regarding the treatment of refractory epilepsy in 
children (Steinborn et al., 2017).
Contraindications for the KD treatment
There are a number of disorders in which the KD can-
not be used. Inborn metabolic defects are the main 
absolute contraindications. Patients with previous fat 
metabolism disorders may present with serious, even 
life-threatening complications after receiving the KD.
The following errors of fat metabolism are the abso-
lute contraindications to the KD:
•	 carnitine deficiency (primary), carnitine palmitoyl-
transferase (CPT) I or II deficiency, carnitine trans-
locase deficiency
•	 β-oxidation defects: medium-chain acyl dehydroge-
nase deficiency (MCAD), long-chain acyl dehydroge-
nase deficiency (LCAD), short-chain acyl dehydro-
genase deficiency (SCAD), long-chain 3-hydroxya-
cyl-CoA deficiency, medium chain 3-hydroxyacyl-
CoA deficiency.
In addition, the following disorders constitute abso-
lute contraindications to the KD: pyruvate carboxylase 
deficiency, porphyria, glycogen storage diseases (except 
type 2), prolonged QT syndrome or other cardiac dis-
eases, liver, kidney or pancreatic insufficiency, hyper-
insulinism. The conditions below are listed among rela-
tive contraindications for the KD treatment: inability to 
maintain adequate nutrition, surgical focus identified 
by neuroimaging and video EEG monitoring, parent or 
caregiver/patient noncompliance, and severe gastroe-
sophageal reflux (Kossoff et al., 2009a; Kossoff, Wang, 
2013; Sharma, Jain, 2014; van der Louw et al., 2016). The 
KD should not be used in patients with renal stones or 
hyperlipidaemia (Vezyroglou, Cross, 2016).
The KD and AEDs
There are no significant contraindications to the simul-
taneous use of the KD and AEDs. Usually, the diet is 
added to previously used medicines (except when it is 
used as the first-line treatment). The prospect of dis-
continuing medication is generally, in addition to sei-
zure control, the main expectation of patients/caregiv-
ers. However, making changes in their administration 
is not recommended for at least the first 3 months. Af-
ter this period, if the KD is effective, it is possible to dis-
continue or reduce AEDs, but there is no numerical data 
available. Weaning off PB and benzodiazepines is more 
likely to cause seizure aggravation compared to other 
medicines (Kossoff et al., 2009 a; McArtney et al., 2017).
The influence of the KD on the absorption of AE-
Ds may be significant due to the nausea and vomiting 
often observed at the beginning, as well as due to the 
slowed gastric emptying induced by the diet. These con-
ditions may lead to a decreased concentration of AEDs 
and in consequence to a transient exacerbation of sei-
zures. Sometimes during KD implementation, the con-
centration of drugs in the blood temporarily increases 
compared to previous levels (changes in pH, decreased 
protein intake, decreased urinary excretion) – in the 
case of PB even up to 100%. Besides that, during treat-
ment with the KD no significant differences in the 
concentration of AEDs compared to the pre-diet peri-
od have been noted (Zupec-Kania et al., 2013; McArt-
ney et al., 2017). Despite many years of combined use of 
AEDs and the KD, there are only a few reports availa-
ble on their pharmacodynamic interaction (McArtney 
et al., 2017). Morrison et al. (2009) analysed a group of 
115 children simultaneously treated with the KD and 
different AEDs: levetiracetam (LEV), LTG, PB, topira-
mate (TPM), VPA and zonisamide (ZNS). They stated 
that children receiving PB were significantly less likely 
to have a > 50% seizure reduction than children treat-
ed with other AEDs (p = 0.003). This result, as well as 
the previously described potential increase in PB con-
centration in the blood, suggest that their simultaneous 
use should be avoided. The opposite effect occurred in 
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children treated with ZNS – the probability of a > 50% 
seizure reduction compared to those receiving other 
medicines was significantly higher (p = 0.04) (Morri-
son et al., 2009). This result may indicate a synergistic 
effect of the KD and ZNS. The use of the KD in com-
bination with a VNS is another example of a synergis-
tic interaction (Kossoff et al., 2009 a).
Taking into account the huge number of patients 
treated simultaneously with the KD and AEDs, their 
mutual adverse interactions are rarely observed; howev-
er, particular attention should be paid to the concurrent 
use of the KD and VPA. Ballaban-Gil et al. (1998) noted 
that most adverse effects, including serious ones such 
as severe hypoproteinemia, fatty liver disease or Fanco-
ni syndrome, occurred in children who received VPA 
at the same time as the KD. This was not confirmed in 
later reports. Other authors did not find a significant 
difference in adverse effects between children receiv-
ing VPA compared to those treated with other medi-
cines (Kang et al., 2004; Lyczkowski et al., 2005). Re-
cently, the problem of the impact of the KD on AEDs 
used simultaneously has again attracted interest. Heo 
et al. (2017) analysed 139 patients with refractory epi-
lepsy treated simultaneously with the KD and AEDs as 
a mono or polytherapy. They compared serum concen-
trations of AEDs (CBZ, LTG, LEV, TPM, OXC, PB, PHT, 
and VPA) prior to the introduction of the KD and dur-
ing treatment. Important differences were found only 
in the case of VPA – a statistically significant (p < 0.001) 
decrease in concentration, and PB – an increase in con-
centration, although not statistically significant, which 
points to the need to closely monitor their levels after 
commencing the KD (Heo et al., 2017). Spilioti et al. 
(2016) observed a rapid increase in ketosis, with clini-
cal symptoms, after discontinuation of VPA in 2 four-
year-old girls with refractory epilepsy (out of 73 patients 
receiving the KD, combined with VPA). Stevens et al. 
(2016) described the case of an 18-month-old girl re-
ceiving TPM and VPA at constant doses, who present-
ed with liver failure symptoms several days after add-
ing the KD. Following her recovery, the KD was used 
again without VPA, and this time no complications 
were observed. This particular interaction between the 
KD and VPA can be put down to common metabolic 
pathways. VPA competes with fatty acids in the pro-
cess of beta oxidation in the liver and slows their con-
version into ketone bodies. During treatment with the 
KD, due to the lower binding capacity of proteins, the 
free fraction of VPA, which may exert a hepatotoxic ef-
fect, increases, but excretion of the drug is also higher 
(Spilioti et al., 2016; Heo et al., 2017). These facts indi-
cate that caution should be exercised when simultane-
ously using the KD and VPA; additionally, blood levels 
should be monitored and doses changes as necessary. 
It should be noted that, drugs that are carbonic anhy-
drase inhibitors (TPM, ZNS), as well as the KD (espe-
cially in the early phase of treatment), predispose pa-
tients to metabolic acidosis (a lowered blood concentra-
tion of bicarbonates) and also to kidney stones. There-
fore, if they are used simultaneously with the KD, it is 
recommended to monitor the level of bicarbonates and 
consider their possible supplementation (Takeoka et al., 
2002; Zupec-Kania et al., 2013; McArtney et al., 2017).
Adverse effects of the ketogenic diet
The KD, like any medical therapy for serious illness-
es, may cause adverse effects. Most of them are mild, 
can be prevented, and if they occur, can be fairly eas-
ily treated (Kossoff et al., 2009 a). In the early stages, 
when introducing the KD, the following adverse effects 
are most common: dehydration, transient hypoglycae-
mia (< 40 mg/dl), hyperketosis, metabolic acidosis, gas-
trointestinal disorders (vomiting, diarrhoea, abdomi-
nal pain, constipation), anorexia, sensation of hunger, 
exacerbation of symptoms of gastroesophageal reflux, 
and lethargy. These occur despite the earlier exclusion 
of contraindications to the use of the KD and are not 
significantly related to the method of initiation (with 
or without fasting) although, according to some au-
thors, they are more common in children who endure 
interruption in feeding, especially <2 years old. They 
are mainly transient and can be fairly easily remedied. 
Only rarely are they the reason to discontinue KD treat-
ment (Kim et al., 2004; Kang et al., 2004; Bergquist et al., 
2005; Kossoff et al., 2008b; Kossoff et al., 2009a; Luat 
et al., 2016; Lin et al., 2017; Cai et al., 2017).
A number of ‘distant’ adverse effects that appear on-
ly after a few weeks, months or years of treatment with 
the KD are also known.
Kidney stones may occur in 5–10% of patients (in 
25% of patients treated with KD for more than 6 years). 
They can be prevented via adequate fluid supply and ad-
ministration of citrate preparations, especially potassi-
um citrate, which increases the excretion of citrates in 
the urine and reduces hypercalciuria. This action re-
duces the risk of nephrolithiasis to 0.9%. The risk of 
developing kidney stones may be slightly higher in pa-
tients receiving carbonic anhydrase inhibitors (aceta-
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zolamide, TPM, ZNS) (Kossoff et al., 2009 a; McNally 
et al., 2009; Paul et al., 2010; Kossoff, Wang, 2013; Zu-
pec-Kania et al., 2013).
Relatively often, in 14–59% (Kossoff et al., 2009a) of 
patients treated with the KD, dyslipidemia (hypertri-
glyceridemia, hypercholesterolemia) is observed. Re-
cently, the problem of lipid profile disorders during the 
use of the KD – as well as their potential link with car-
diovascular diseases – has generated interest amongst 
many authors. Zamani et al. (2016) assessed the lipid 
profile in the course of KD treatment in 33 children, 
finding a significant increase in total cholesterol, LDL 
and triglycerides (p < 0.001), with very good efficacy 
(in 63% reduction of seizures was > 50%). Cervenka et 
al. (2016c) evaluated the impact of the MAD on the li-
pid profile of adult patients with refractory epilepsy. 
They observed an increase in total and LDL choles-
terol (p = 0.01), with the correct triglyceride level after 
3 months of treatment, and the absence of cardiovascu-
lar or cerebrovascular events. These values normalised 
naturally during the year and remained at a normal lev-
el in patients whose treatment duration even exceeded 
3 years. In a prospective study on 38 patients, Azevedo 
de Lima et al. (2017) assessed the effect of the KD on 
any increase in triglycerides, total cholesterol, LDL and 
HDL, but also on apolipoproteins (ApoA-1 and ApoB) 
and a small LDL subfraction. These molecules have 
a particularly atherogenic effect on vascular walls. Al-
terations in the lipid profile in patients with refractory 
epilepsy result not only from the KD but also from the 
impact of some AEDs (CBZ, PHT, VPA) favouring ‘dys-
lipidemia’ by stimulation of cytochrome P 450. These 
observations, without undermining the benefits of the 
KD in the treatment of drug-resistant epilepsy, indicate 
the need to monitor not only the classic lipid profile 
but also its subfractions. Dyslipidemia mostly resolves 
spontaneously during treatment or after interventions 
such as reducing the ketogenic ratio, administering car-
nitine, adding MCT oil to the diet or adding polyun-
saturated fatty acids (PUFAs) (Kang et al., 2004; Niza-
muddin et al., 2008; Kossoff et al., 2009a; Zupec-Kania 
et al., 2013; Yoon et al., 2013; Yoon et al., 2014; Cerven-
ka, Kossoff, 2013; Luat et al., 2016; Ułamek-Kozioł et 
al., 2016; Cai et al., 2017; Azevedo de Lima et al., 2017).
The impact of the KD on the cardiovascular system’s 
functioning was also examined, and no significant af-
fects were observed. The effect of dyslipdemia on the 
carotid intima media thickness was not confirmed af-
ter 12 months of using KD, although a decrease in its 
distensibility was observed compared to baseline val-
ues. This parameter normalized after 24 months (Cai 
et al., 2017; Luat et al., 2016). Ozdemir et al. (2016) in 
a prospective study of 61 children treated with the KD, 
did not observe any negative impact on cardiac systolic 
and diastolic functions. The delayed impact of the KD 
on the cardiovascular system requires further research.
Among the adverse effects of the KD related to the 
cardiovascular system, a prolonged QT interval is list-
ed (Kang et al., 2004; Hartman, Vining, 2007; Kossoff 
et al., 2009 a, Elia et al., 2017) as is the rare, but serious 
complication – cardiomyopathy. Their occurrence is as-
sociated with selenium deficiency observed during KD 
treatment (Kang et al., 2004, Cervenka, Kossoff, 2013). 
Arslan demonstrated this deficiency’s presence after 
6 and 12 months of therapy in almost half (49.1%) of 
110 patients assessed, however none of them was diag-
nosed with clinical, electrocardiographic or echocardi-
ographic abnormalities. These results suggest the need 
to monitor selenium levels, and if necessary, use sele-
nium supplements during treatment with the KD (Ar-
slan et al., 2016). Supplementation during treatment is 
also required for vitamins, minerals and trace elements, 
insufficient in the KD, as their deficiency may be the 
reason for clinical disorders (Kossoff et al., 2009a; Cer-
venka, Kossoff, 2013; Luat et al., 2016; Cai et al., 2017). 
The KD, as well as concomitantly used AEDs, espe-
cially VPA, increases the risk of carnitine deficiency, 
clinically manifested by weakness, decreased muscle 
strength, hypotonia, fatigue, apathy and also anaemia, 
cardiomyopathy or disorders of liver function. Hence 
there is a need to monitor its level in the course of treat-
ment. Should the level of free carnitine be reduced, or 
clinical symptoms of its deficiency occur, supplemen-
tation must be introduced. Some authors recommend 
prophylactic administration of carnitine in patients on 
the KD (Kang et al., 2004; Kossoff et al., 2009b; Cer-
venka, Kossoff, 2013; Fliciński et al., 2016).
Long-term use of the KD may also lead to deminer-
alization and increased bone fragility. Groesbeck et al. 
(2006) reported bone fractures in 21% of 28 children 
treated with the KD for more than 6 years. Bergquist et 
al. (2008) confirmed progressive bone mineral content 
loss during treatment with the KD. Besides inadequate 
dietary supply of calcium and vitamin D, the cause of 
these disorders is also associated with acidosis occur-
ring during KD treatment, poorer nutritional status 
linked with chronic disease and long-term use of medi-
cation affecting the calcium-phosphate balance already 
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prior to the diet. These complications can be prevent-
ed by calcium and vitamin D supplementation as well 
as by, during the use of the KD, avoidance/prevention 
of excessive metabolic acidosis (by the administration 
of alkalinising agents, especially if the patient receives 
carbonic anhydrase inhibitors). In the case of longer use 
of the diet, the need to periodically repeat densitomet-
ric tests (DEXA) is stressed (Kang et al., 2004; Groes-
beck et al., 2006; Bergquist et al., 2008; Yuen et al., 2017). 
Slowed growth, observed in a relatively large number of 
children on the KD, even according to some authors in 
more than 80%, has not been entirely explained. Young-
er children are most exposed to this risk. Its occurrence 
is more likely in the presence of chronic acidosis and 
insufficient protein intake. Therefore, monitoring the 
progress of growth in children is essential, especially 
in those treated with the KD for a long time (Bergquist 
et al., 2008; Kossoff et al., 2009a; van der Louw et al., 
2016; Luat et al., 2016; Cai et al., 2017).
A high-fat diet can also cause uncommon but danger-
ous complications such as liver dysfunction and pancre-
atitis. There is a risk of an increased level of transam-
inases (in general < 200 mg/dl), sometimes already at 
the beginning of the treatment, a fatty liver after about 
6 months and the formation of gallstones 12 months in-
to the diet. The association of toxic liver damage with 
simultaneous use of VPA during the KD and also with 
carnitine deficiency, is stressed. These complications 
are usually reversible and do not require discontinua-
tion of the diet. Patients treated with the KD should be 
monitored regularly in order to detect potential adverse 
effects on the liver (ultrasound, transaminase). If pan-
creatitis occurs (a very rare but life-threatening com-
plication), discontinuation of the KD should be consid-
ered (Kang et al. 2004; Cervenka, Kossoff, 2013; Arslan 
et al., 2016; Stevens et al., 2016).
The increased incidence of infection, without clear-
ly confirmed immune disorders, is mentioned among 
rarely described, although quite common, adverse ef-
fects associated with the KD. Generalised severe infec-
tions have been sporadically reported (Kang et al., 2004; 
Cervenka, Kossoff, 2013).
The KD may also be accompanied by hypoproteine-
mia, occurring in about 10% of treated patients. Its 
cause, apart from the limited but adequate supply of 
protein in the diet, and increased gluconeogenesis re-
sulting from the low supply of carbohydrates, is hard 
to explain (Kang et al., 2004). It can usually be com-
pensated for by increasing the supply of protein in the 
diet (e.g. by reducing the ketogenic ratio). Reports on 
single cases of protein-losing entheropathy during KD 
treatment, sometimes following a difficult course, shed 
some light on this problem. Abdominal dynamic scin-
tigraphy may be useful in diagnosing the cause of hy-
poproteinemia occurring in the course of treatment 
with the KD (Moriyama et al., 2015; Ahn et al., 2017).
Hyperuricemia, hyponatremia, hypomagnesemia, 
and zinc deficiency, are also mentioned among the bi-
ochemical abnormalities that may occur during the use 
of the KD, but they are easily correctable (Kang et al., 
2004; Kossoff et al., 2009 a; Cervenka, Kossoff, 2013). 
The impact of the KD on haematological parameters 
was assessed in a group of 33 children with refractory 
epilepsy. A statistically significant increase was found 
after 6 and 12 months in the haemoglobin, haematocrit, 
MCV and after 12 months in Vit B12 (Kose et al., 2018).
Although the KD can cause a number of adverse ef-
fects, they are not the main reason for interrupting the 
therapy. Usually, the treatment is discontinued due to 
a lack of satisfactory efficacy (49.9%), or difficulty in 
adapting to its restrictions (11%). Adverse effects are 
mostly mild and easy to manage or can be prevented. 
The occurrence of more serious, potentially fatal com-
plications, is not more frequent than during the natu-
ral course of symptomatic epilepsy in children. Fur-
ther studies are needed to assess the long-term effect of 
the KD on health, even many years after the end of the 
treatment. The potential link between hyperlipidaemia, 
even transient, and the development of atherosclerosis 
and cardiovascular diseases later in life should be ex-
amined in particular (Cai et al., 2017).
Cost effectiveness of the KD
Several recently published studies have attempted to 
assess the economic aspect of the KD in the treatment 
of refractory epilepsy in comparison to pharmacolog-
ical treatment (care as usual – CAU) and the VNS. The 
cost differences between KD and CAU were not con-
siderable. The VNS, compared to standard treatment 
and KD, was more expensive over a 12-month peri-
od, while over 5 years it was definitely more econom-
ically advantageous (de Kinderen et al., 2011; de Kin-
deren et al., 2015; de Kinderen et al., 2016; Wijnen et 
al., 2017). In addition, the number of hospital admis-
sions and visits to the hospital emergency department 
was analysed in a group of 37 children with refracto-
ry epilepsy. A 12-month period of treatment with the 
KD was compared to the 12 months prior to its intro-
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duction. The number of visits to the emergency unit 
decreased by 36%, and there were also 40 % fewer hos-
pitalisations with a 39% reduction in hospital days. As 
a result, there was a decrease in the cost associated with 
hospital treatment and emergency department inter-
ventions in the group of children treated with the KD 
(Kayyali et al., 2016). This issue also requires further 
long-term research on larger groups of patients taking 
into account the direct and indirect costs of each form 
of therapy used.
CONCLUSIONS AND FUTURE PROSPECTS
1. The KD is currently a well-established therapy for 
refractory epilepsy in children. Its efficacy has 
been confirmed not only by clinical observations 
in groups of patients or individual cases, but also 
by randomised trials.
2. There has been an increasing number of reports on 
the successful use of the KD in adult patients, espe-
cially its more liberal versions such as the MAD or 
the LGIT.
3. The KD is particularly effective in some forms of ep-
ilepsies, and should be considered at an early stage of 
treatment (MAE, Dravet syndrome, West syndrome, 
FIRES); and diseases in which it is the treatment of 
choice (GLUT1 DS, PDHD).
4. The KD has also found application in the treatment 
of urgent conditions such as SRSE.
5. Extensive experience in the KD therapy allows to 
avoid or successfully treat potential adverse effects, 
which results in greater efficacy and safety of the 
treatment.
6. The KD should always be considered, after exclud-
ing contraindications, as a therapeutic option in pa-
tients diagnosed with refractory epilepsy, regardless 
of their age. It should not be perceived as a treatment 
of last resort.
7. Due to the rapidly growing number of children treat-
ed with the KD, ‘adult’ neurologists should offer this 
therapy to their patients as well.
8. Further research on the mechanism of action of 
the KD, its effectiveness in particular epilepsy syn-
dromes, and potential long-term adverse effects is 
needed.
9. Possible simplification of the use of the KD, which 
might lead to its wider application, is also worth 
investigating.
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